{"schema_version":"secwatch.filing_event.v1","accession":"0000872589-26-000014","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.841405+00:00","generated_at":"2026-05-15T02:36:43.969769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut","bullets":["Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.","EYLEA HD U.S. net sales $468M (+52%); EYLEA HD+EYLEA total U.S. down 10% to $941M.","Dupixent global net sales (Sanofi) up 33% to $4.9B; new approvals for CSU in children and AFRS.","New $3.0B share repurchase authorized; $803M bought back in Q1; dividend $0.94/share.","FY2026 GAAP gross margin guidance reduced to 77%-78% from 79%-80% due to Limerick plant disruption."],"urls":{"canonical":"https://secwatch.observer/filing/0000872589-26-000014","json":"https://secwatch.observer/filing/0000872589-26-000014.json","markdown":"https://secwatch.observer/filing/0000872589-26-000014.md","text":"https://secwatch.observer/filing/0000872589-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/0000872589-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000014/regn-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:36:43.969769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}